Inhibitors of the intrinsic pathway, such as agents targeting FXI or FXII that are in current clinical development [54], may be particularly useful in reducing the risk of venous thromboembolism in patients undergoing HPB surgery. This evidence concerns the gene F11 and venous thromboembolism.